$BCDA

Altman Peter purchased $4K of BCDA

Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.78 on 2026-07-29.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 29, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

This is an insider open-market purchase by the CEO, but the disclosure does not include new company performance, guidance, or external events that would materially change valuation expectations.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is not a standalone fundamental catalyst.

03

What to watch

The filing lacks any accompanying company-specific catalyst (guidance, trial results, financing, or regulatory updates), limiting tradable conclusions.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-29 (same day as transaction)

Background

The article is a primary-source SEC Form 4 insider transaction for BioCardia, Inc. (BCDA).

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,000 shares at $0.7800 on 2026-07-29.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the article provides no new operational, financial, or regulatory catalyst, and the transaction size is modest relative to typical market-moving events.

Market effects

No sector-wide read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys on Form 4 can reflect routine liquidity needs or diversification rather than a strong forward-looking signal, especially without a 10b5-1 plan context.

Key entities

  • BioCardia, Inc.

    Subject of the Form 4 insider transaction; CEO Altman Peter purchased 5,000 shares at $0.7800 on 2026-07-29.

  • Altman Peter

    President and CEO and reporting person on the Form 4; direct ownership purchase.

Related articles